These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 20163245)

  • 21. Glycogen storage disease type Ia in canines: a model for human metabolic and genetic liver disease.
    Specht A; Fiske L; Erger K; Cossette T; Verstegen J; Campbell-Thompson M; Struck MB; Lee YM; Chou JY; Byrne BJ; Correia CE; Mah CS; Weinstein DA; Conlon TJ
    J Biomed Biotechnol; 2011; 2011():646257. PubMed ID: 21318173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term correction of murine glycogen storage disease type Ia by recombinant adeno-associated virus-1-mediated gene transfer.
    Ghosh A; Allamarvdasht M; Pan CJ; Sun MS; Mansfield BC; Byrne BJ; Chou JY
    Gene Ther; 2006 Feb; 13(4):321-9. PubMed ID: 16195703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rescue administration of a helper-dependent adenovirus vector with long-term efficacy in dogs with glycogen storage disease type Ia.
    Crane B; Luo X; Demaster A; Williams KD; Kozink DM; Zhang P; Brown TT; Pinto CR; Oka K; Sun F; Jackson MW; Chan L; Koeberl DD
    Gene Ther; 2012 Apr; 19(4):443-52. PubMed ID: 21654821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In Vivo Zinc Finger Nuclease-mediated Targeted Integration of a Glucose-6-phosphatase Transgene Promotes Survival in Mice With Glycogen Storage Disease Type IA.
    Landau DJ; Brooks ED; Perez-Pinera P; Amarasekara H; Mefferd A; Li S; Bird A; Gersbach CA; Koeberl DD
    Mol Ther; 2016 Apr; 24(4):697-706. PubMed ID: 26865405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene therapeutic prospects in early onset of severe retinal dystrophy: restoration of vision in RPE65 Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium.
    Rolling F; Le Meur G; Stieger K; Smith AJ; Weber M; Deschamps JY; Nivard D; Mendes-Madeira A; Provost N; Péréon Y; Cherel Y; Ali RR; Hamel C; Moullier P; Rolling F
    Bull Mem Acad R Med Belg; 2006; 161(10-12):497-508; discussion 508-9. PubMed ID: 17503728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular biology and gene therapy for glycogen storage disease type Ib.
    Chou JY; Cho JH; Kim GY; Mansfield BC
    J Inherit Metab Dis; 2018 Nov; 41(6):1007-1014. PubMed ID: 29663270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complete normalization of hepatic G6PC deficiency in murine glycogen storage disease type Ia using gene therapy.
    Yiu WH; Lee YM; Peng WT; Pan CJ; Mead PA; Mansfield BC; Chou JY
    Mol Ther; 2010 Jun; 18(6):1076-84. PubMed ID: 20389290
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mice expressing reduced levels of hepatic glucose-6-phosphatase-α activity do not develop age-related insulin resistance or obesity.
    Kim GY; Lee YM; Cho JH; Pan CJ; Jun HS; Springer DA; Mansfield BC; Chou JY
    Hum Mol Genet; 2015 Sep; 24(18):5115-25. PubMed ID: 26089201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adenovirus-mediated gene therapy in a mouse model of glycogen storage disease type 1a.
    Chou JY; Zingone A; Pan CJ
    Eur J Pediatr; 2002 Oct; 161 Suppl 1():S56-61. PubMed ID: 12373573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatic mitochondrial dysfunction is a feature of Glycogen Storage Disease Type Ia (GSDIa).
    Farah BL; Sinha RA; Wu Y; Singh BK; Lim A; Hirayama M; Landau DJ; Bay BH; Koeberl DD; Yen PM
    Sci Rep; 2017 Mar; 7():44408. PubMed ID: 28317891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors.
    Fraites TJ; Schleissing MR; Shanely RA; Walter GA; Cloutier DA; Zolotukhin I; Pauly DF; Raben N; Plotz PH; Powers SK; Kessler PD; Byrne BJ
    Mol Ther; 2002 May; 5(5 Pt 1):571-8. PubMed ID: 11991748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neonatal gene therapy of glycogen storage disease type Ia using a feline immunodeficiency virus-based vector.
    Grinshpun A; Condiotti R; Waddington SN; Peer M; Zeig E; Peretz S; Simerzin A; Chou J; Pann CJ; Giladi H; Galun E
    Mol Ther; 2010 Sep; 18(9):1592-8. PubMed ID: 20571544
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Restoration of vision in RPE65-deficient Briard dogs using an AAV serotype 4 vector that specifically targets the retinal pigmented epithelium.
    Le Meur G; Stieger K; Smith AJ; Weber M; Deschamps JY; Nivard D; Mendes-Madeira A; Provost N; Péréon Y; Cherel Y; Ali RR; Hamel C; Moullier P; Rolling F
    Gene Ther; 2007 Feb; 14(4):292-303. PubMed ID: 17024105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucose-6-phosphatase deficiency.
    Froissart R; Piraud M; Boudjemline AM; Vianey-Saban C; Petit F; Hubert-Buron A; Eberschweiler PT; Gajdos V; Labrune P
    Orphanet J Rare Dis; 2011 May; 6():27. PubMed ID: 21599942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer.
    Choi JO; Lee MH; Park HY; Jung SC
    J Biomed Sci; 2010 Apr; 17(1):26. PubMed ID: 20398385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correction of glycogen storage disease type 1a in a mouse model by gene therapy.
    Zingone A; Hiraiwa H; Pan CJ; Lin B; Chen H; Ward JM; Chou JY
    J Biol Chem; 2000 Jan; 275(2):828-32. PubMed ID: 10625614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improvement of Photoreceptor Targeting via Intravitreal Delivery in Mouse and Human Retina Using Combinatory rAAV2 Capsid Mutant Vectors.
    Reid CA; Ertel KJ; Lipinski DM
    Invest Ophthalmol Vis Sci; 2017 Dec; 58(14):6429-6439. PubMed ID: 29260200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors.
    Mah C; Pacak CA; Cresawn KO; Deruisseau LR; Germain S; Lewis MA; Cloutier DA; Fuller DD; Byrne BJ
    Mol Ther; 2007 Mar; 15(3):501-7. PubMed ID: 17245350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic Correction of Murine Glycogen Storage Disease Type IV by an AAV-Mediated Gene Therapy.
    Yi H; Zhang Q; Brooks ED; Yang C; Thurberg BL; Kishnani PS; Sun B
    Hum Gene Ther; 2017 Mar; 28(3):286-294. PubMed ID: 27832700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo.
    Pacak CA; Mah CS; Thattaliyath BD; Conlon TJ; Lewis MA; Cloutier DE; Zolotukhin I; Tarantal AF; Byrne BJ
    Circ Res; 2006 Aug; 99(4):e3-9. PubMed ID: 16873720
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.